相似文献
1
Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.
Semin Cell Dev Biol. 2015 Apr;40:127-33. doi: 10.1016/j.semcdb.2015.03.010. Epub 2015 Apr 4.
2
Calcium Signaling, PKC Gamma, IP3R1 and CAR8 Link Spinocerebellar Ataxias and Purkinje Cell Dendritic Development.
Curr Neuropharmacol. 2018 Jan 30;16(2):151-159. doi: 10.2174/1570159X15666170529104000.
3
Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - A therapeutic opportunity?
Biochem Biophys Res Commun. 2017 Feb 19;483(4):998-1004. doi: 10.1016/j.bbrc.2016.09.053. Epub 2016 Sep 15.
4
Keeping Our Calcium in Balance to Maintain Our Balance.
Biochem Biophys Res Commun. 2017 Feb 19;483(4):1040-1050. doi: 10.1016/j.bbrc.2016.07.020. Epub 2016 Jul 5.
5
Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction.
Sci China Life Sci. 2011 Aug;54(8):752-62. doi: 10.1007/s11427-011-4205-7. Epub 2011 Jul 24.
6
Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA).
Int J Mol Sci. 2019 Dec 27;21(1):216. doi: 10.3390/ijms21010216.
7
TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease.
Brain Res Mol Brain Res. 2004 Jun 18;125(1-2):120-8. doi: 10.1016/j.molbrainres.2004.03.018.
8
Can the calcium hypothesis explain synaptic loss in Alzheimer's disease?
Neurodegener Dis. 2014;13(2-3):139-41. doi: 10.1159/000354778. Epub 2013 Sep 24.
9
Roles of inositol 1,4,5-trisphosphate receptors in spinocerebellar ataxias.
Neurochem Int. 2016 Mar;94:1-8. doi: 10.1016/j.neuint.2016.01.007. Epub 2016 Jan 28.
10
Calcium homeostasis and spinocerebellar ataxia-1 (SCA-1).
Brain Res Bull. 2001;56(3-4):221-5. doi: 10.1016/s0361-9230(01)00595-0.
引用本文的文献
1
The potential of olfaction loss to induce cognitive impairment and anxiety behavior in mice via the microbiota-gut-brain axis.
Front Microbiol. 2025 Jul 2;16:1595742. doi: 10.3389/fmicb.2025.1595742. eCollection 2025.
2
Automated gait analysis indicates efficacy of T-type calcium channel inhibition for mitigation of disrupted calcium signalling in an SCA5 mouse model.
Sci Rep. 2025 Jul 1;15(1):20990. doi: 10.1038/s41598-025-05511-1.
3
Calcium Ions in the Physiology and Pathology of the Central Nervous System.
Int J Mol Sci. 2024 Dec 6;25(23):13133. doi: 10.3390/ijms252313133.
4
Expanded ATXN1 alters transcription and calcium signaling in SCA1 human motor neurons differentiated from induced pluripotent stem cells.
Neurobiol Dis. 2024 Oct 15;201:106673. doi: 10.1016/j.nbd.2024.106673. Epub 2024 Sep 20.
5
Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases.
Biology (Basel). 2023 Dec 7;12(12):1504. doi: 10.3390/biology12121504.
6
Modulating mitochondrial calcium channels (TRPM2/MCU/NCX) as a therapeutic strategy for neurodegenerative disorders.
Front Neurosci. 2023 Oct 20;17:1202167. doi: 10.3389/fnins.2023.1202167. eCollection 2023.
7
Restoring calcium homeostasis in Purkinje cells arrests neurodegeneration and neuroinflammation in the ARSACS mouse model.
JCI Insight. 2023 Jun 22;8(12):e163576. doi: 10.1172/jci.insight.163576.
8
Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models.
Neurotherapeutics. 2023 Jan;20(1):48-66. doi: 10.1007/s13311-023-01357-5. Epub 2023 Apr 5.
9
Differential mitochondrial and cellular responses between H vs. J mtDNA haplogroup-containing human RPE transmitochondrial cybrid cells.
Exp Eye Res. 2022 Jun;219:109013. doi: 10.1016/j.exer.2022.109013. Epub 2022 Mar 10.
10
Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.
Int J Mol Sci. 2022 Jan 6;23(2):624. doi: 10.3390/ijms23020624.
本文引用的文献
1
Therapeutic prospects for spinocerebellar ataxia type 2 and 3.
Drugs Future. 2009 Dec;34(12). doi: 10.1358/dof.2009.034.12.1443434.
2
Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.
Biol Psychiatry. 2015 Apr 15;77(8):729-39. doi: 10.1016/j.biopsych.2014.10.013. Epub 2014 Oct 29.
3
A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Neurobiol Dis. 2015 Jan;73:174-88. doi: 10.1016/j.nbd.2014.09.020. Epub 2014 Oct 7.
4
Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
Annu Rev Pharmacol Toxicol. 2015;55:419-37. doi: 10.1146/annurev-pharmtox-010814-124309. Epub 2014 Oct 1.
5
Pulling complexes out of complex diseases: Spinocerebellar Ataxia 7.
Rare Dis. 2014 Apr 14;2:e28859. doi: 10.4161/rdis.28859. eCollection 2014.
6
Ataxia and Purkinje cell degeneration in mice lacking the CAMTA1 transcription factor.
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11521-6. doi: 10.1073/pnas.1411251111. Epub 2014 Jul 21.
7
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.
8
Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice.
Neuron. 2014 Apr 2;82(1):79-93. doi: 10.1016/j.neuron.2014.02.019.
9
Targeting the β secretase BACE1 for Alzheimer's disease therapy.
Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17.
10
The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease.
Channels (Austin). 2014;8(3):230-42. doi: 10.4161/chan.27471.
Zotero 插件